CuraSen Therapeutics has commenced its Phase IIa proof-of-concept trial of CuraAX (CST-3056) with dosing of the first patient ...
1dOpinion
Opinion: A wider look at kratom and Connecticut. Synthetic derivatives and natural leaves differ
While not risk-free, natural leaf kratom offers an accessible option, and many users report that it helps them regain control ...
Functional vision improvements are reported, with optimal pupil size considerations for varying light conditions being ...
A study conducted by researchers at the Center for Redox Processes in Biomedicine (Redoxoma) has shown that ATP-sensitive ...
CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in ...
Background Since the 1960s, beta blockers have been used to treat hypertrophic obstructive cardiomyopathy (HOCM), a genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback